abl103
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 23, 2023 (NCT06126666)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFRSF9 inhibitor
inhibitor - VTCN1
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07158918 | Phase 1/Phase 2 (Phase 2) | Aug 6, 2025 | ABL Bio Inc., Merck |
| NCT06126666 | Phase 1 | Nov 23, 2023 | ABL Bio Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ABL Bio Inc. | For profit | 2 | 2 | 2 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1